TD 1439

Drug Profile

TD 1439

Alternative Names: TD-1439

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance Biopharma
  • Class Small molecules
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 01 Apr 2017 Theravance Biopharma completes a phase I trial in Cardiovascular disorders (In adults, In the elderly, In volunteers) and Kidney disorders (In adults, In the elderly, In volunteers) in USA (PO) (NCT02954263)
  • 27 Feb 2017 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers released by Theravance
  • 27 Feb 2017 Theravance completes a phase I single ascending dose trial in Cardiovascular and kidney disorders (In adults, In volunteers) in USA (NCT02903095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top